Ocugen, Inc. (OCGN)
| Market Cap | 364.56M |
| Revenue (ttm) | 42,620 |
| Net Income (ttm) | -18.20M |
| Shares Out | 141.59M |
| EPS (ttm) | 3.80 |
| PE Ratio | 0.58 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $2.20 |
| Previous Close | $2.25 |
| Change ($) | -0.05 |
| Change (%) | -2.22% |
| Day's Open | 2.22 |
| Day's Range | 2.17 - 2.25 |
| Day's Volume | 10,152,637 |
| 52-Week Range | 0.20 - 3.07 |
Ocugen is hanging on by a thread with its latest Indian biotech deal. OCGN stock looks to be a highly speculative play with a negative expected return.
Celebrating Ocugen's value-added collaboration to develop a potentially lifesaving vaccine is fine, but OCGN stock might be too pricey now. The post Ocugen Stock Looks Overinflated appeared fi...
New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investor...
The biotech unexpectedly canceled a stockholder meeting scheduled for Wednesday.
MALVERN, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindnes...
With risk-return not in your favor, steer clear of these 8 penny stocks, all of which could see big declines as the new year unfolds. Chesapeake Energy (OTCMKTS:CHKAQ) Genius Brands (NASDAQ:GN...
MALVERN, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindnes...
Investors are excited about big news for Ocugen's Indian partner.
Ocugen shares surged after its Indian development partner got emergency-use authorization for its Covid-19 vaccine. OCGN stock remains one to watch as new virus waves strike.
Investors are right to wonder if this risky biotech has what it takes to develop a new coronavirus vaccine.
Leading experts to evaluate the clinical and regulatory path to approval in the US market of COVAXIN™, a whole-virion inactivated COVID-19 vaccine Leading experts to evaluate the clinical and ...
Ocugen (OCGN) stock is continuing to rise higher on Wednesday following news yesterday concerning a vaccine for the novel coronavirus. The post OCGN Stock: 5 Things for Investors to Know as Oc...
Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized...
OCGN stock is on the move Tuesday after Ocugen announced plans to commercialize and develop a Covid-19 vaccine. The post OCGN Stock: Why Ocugen Shares Are Soaring 130% Today appeared first on ...
Shares of Ocugen Inc (NASDAQ: OCGN), a micro-cap biopharma, gap-opened Tuesday's session higher and are trading with noteworthy gains. What Happened: Malvern, Pennsylvania-based Ocugen said it...
Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the US
MALVERN, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cur...
Ocugen (OCGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
MALVERN, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cur...
MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cur...
Ocugen (OCGN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2021 First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2021
MALVERN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cur...
MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cur...
MALVERN, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cur...
Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned
MALVERN, Pa., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to ...
Probably because it's not a buzzworthy coronavirus stock, you might not hear much about OCGN stock but it still has strong upside potential. The post Biotech Speculators Should Try a Small Pos...
Ocugen continues to conduct at-the-market offerings to raise capital. But with a distant payoff, OCGN stock offers too much risk and not enough reward.
MALVERN, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies t...
Because of the pandemic, OCGN stock attracts speculative interest. But it is not likely to pay off in the long-run The post If the FDA Can’t Help Ocugen Stock, You Have to Wonder Who Can appe...
In analyzing the science behind OCGN stock, the innovation is quite profound. However, it’s this very platform that is under serious scrutiny thanks to the coronavirus.
OCGN stock isn't the next great biotech play, but savvy traders can limit its risk. The post The Risk-Reward Ratio of Ocugen Stock Is Positive appeared first on InvestorPlace.
MALVERN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing ...
Because of the dynamics of the new normal, troubled names like OCGN stock continue to attract speculative interest. Perhaps some math will finally dissuade these gamblers?
While Ocugen is unprofitable and in bad need of cash, OCGN stock could soar if its eye disease therapies see clinical success. The post For Biopharma Ocugen, Think Speculation In Small Doses a...
MALVERN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies t...
Ocugen is raising cash through its orphan drug designation, but it still faces risks. Make sure you treat OCGN stock as a speculation.
OCGN stock has held up despite the failure of what was its flagship drug. The remaining pipeline simply isn't strong enough for investors to risk more capital.
Until we begin to see solid trial results, OCGN stock could easily plunge back to 20 cents a share. Avoid investing in Ocugen for now.
MALVERN, Pa., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to...
There's a good deal of downside risk, but Ocugen is worth a look. OCGN stock is likely to fall as Ocugen raises $30 million or 54% of its equity to fund operations over the next 2 plus years.
Recent news helps the odds for OCGN stock, but speculators have gotten carried away. Don't waste your time (or risk your capital) with this.
Ocugen has no revenue and is years away from developing a product. While the cause of developing therapies to fight blindness is laudable, there's no money to be made with OCGN stock.
Ocugen got good news Aug. 14 announcing a fourth orphan drug designation for its ophthalmology gene therapy.
Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q2 2020 Results - Earnings Call Transcript
OCGN stock has been a hot penny stock. But no revenue and a lead candidate that is years away, are reminders that Ocugen is still a penny stock.
Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program
Some red-hot penny stocks are worth chasing; OCGN stock is not one of them. In fact, this rally is worth fading.
The FDA just gave a special designation to one of Ocugen's flagship products. That is good for science and it's great for OCGN stock.
About OCGN
Ocugen, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic par... [Read more...]
| Industry Biotechnology | |
| CEO Shankar Musunuri | Employees 16 |
| Stock Exchange NASDAQ | Ticker Symbol OCGN |
Analyst Forecasts
According to 4 analysts, the average rating for Ocugen stock is "Buy." The 12-month stock price forecast is 0.90, which is a decrease of -59.09% from the latest price.